Treatment for Children with Childhood Apraxia of Speech

• Register: ANZCTR
• Last refreshed on: 13 January 2020
• Main ID: ACTRN12615000695505
• Date of registration: 03/07/2015
• Prospective Registration: Yes
• Primary sponsor: Mirjana Gomez
• Public title: Treatment for Children with Childhood Apraxia of Speech
• Scientific title: Will children with Childhood Apraxia of Speech benefit from the Kaufman Speech to Language Protocol to improve speech outcomes.
• Date of first enrolment: 16/07/2015
• Target sample size: 10
• Recruitment status: Suspended
• URL: https://anzctr.org.au/ACTRN12615000695505.aspx
• Study type: Interventional
• Study design: Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Efficacy;
• Phase: Not Applicable

Countries of recruitment

Australia

Contacts

• Name: Mrs Mirjana Gomez

• Name: Mrs Mirjana Gomez

Key inclusion & exclusion criteria

Inclusion criteria: Diagnosis of Childhood Apraxia of Speech
3-5 years of age
Normal vision (adjusted to normal eg. wears glasses)
Normal hearing acuity
Child must speak English as primary language.
One parent speaks English as their primary language.
Exclusion criteria: Autism Spectrum Disorder
Known neurological deficits
Intellectual impairment
Structural/oral motor anomalies



Age minimum: 3 Years
Age maximum: 5 Years
Gender: Both males and females

Health Condition(s) or Problem(s) studied

Childhood Apraxia of Speech;
Childhood Apraxia of Speech

Physical Medicine / Rehabilitation - Speech therapy

Intervention(s)

This research will use a single case experimental design with multiple baselines across behaviours and participants. Each child will participate in initial baseline data collection, 3 weeks of individualized and targeted one-on-one treatment using the Kaufman Speech to Language protocol (K-SLP), followed by post treatment maintenance follow up. Initial baselines will comprise of between 3-5 data points randomly assigned to participants to allow for stability in measurement and to determine any clear visual trends before commencement of treatment, and to ensure stable speech production. The data to be collected includes the participant’s production of a predetermined and individualised set of words: including treated words (words that are used during the treatment session), control words (words that are untreated and do not have the same features as treatment words) and foil words (have similar features as the treated words but are untreated). This phase will be conducted in the clinic.

Treatment phase: During the treatment phase, a trained clinician (speech pathologist/trained speech pathology student) will administer treatment as per the K-SLP protocol in the clinic for 60 minutes per day 4 times/week for 3 weeks. Treatment will consist of 20 preselected treatment words. The selection of these words will be based on the chosen sounds or word features that will be the target of the treatment for each client. This will be determined based on the initial pre-test diagnostic assessments. Additionally there will be untreated words- 20 foil words, 20 control words that will have similar features or sounds as the treatment words. Additional data points will be collected every 4th treatment session using the predetermined individualised word lists comprised of words t

Primary Outcome(s)

Motor planning for speech as evaluated by the Diagnostic Evaluation of Articulation and Phonology, Goldman Fristoe Test of Articulation- 2nd edition, DEMMS, T-POT.[1 week, 1 month and 3 month time points post treatment.]

Secondary Outcome(s)

Speech accuracy as evaluated by Goldman Fristoe Test of Articulation- 2nd edition, T-POT, connected speech sample.[1 week, 1 month and 3 months post treatment]

Inventory of sounds as evaluated by Goldman Fristoe Test of Articulation- 2nd edition, T-POT, connected speech sample.[1 week, 1 month and 3 months post treatment]

Percent of correct phonemes (PCC) as evaluated by Goldman Fristoe Test of Articulation- 2nd edition, T-POT, connected speech sample.[1 week, 1 month and 3 months post treatment.]

Secondary ID(s)

Nil known

Ethics review

Status: Approved
Approval date:
Contact:

The University of Sydney Ethics Committee